Treating Japanese Patients With Pembrolizumab for Platinum-Refractory Advanced Urothelial Carcinoma in Real-World Clinical Practice

BACKGROUND: Since December 2017, pembrolizumab has been approved in Japan as a second-line treatment for radical unresectable urothelial carcinoma (UC) that has become exacerbated after chemotherapy by the international randomized phase 3 trial, KEYNOTE-045. The aim of this study was to evaluate the...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Clin Med Res
Glavni autori: Furubayashi, Nobuki, Kuroiwa, Kentaro, Tokuda, Noriaki, Tomoda, Toshihisa, Morokuma, Futoshi, Hori, Yoshifumi, Negishi, Takahito, Inoue, Tomohiro, Kumagai, Masatoshi, Nakamura, Motonobu
Format: Artigo
Jezik:Inglês
Izdano: Elmer Press 2020
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7239584/
https://ncbi.nlm.nih.gov/pubmed/32489505
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14740/jocmr4162
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items